BPG is committed to discovery and dissemination of knowledge
- Number of total visits
-
33031216
- Number of visits today
- 5662
- Number of downloads
-
16219873
MEMBERSHIP
Cited by in F6Publishing
| Number |
Citing Articles |
| 1 |
Nhu QM, Aceves SS. Current state of biologics in treating eosinophilic esophagitis. Ann Allergy Asthma Immunol 2023;130:15-20. [PMID: 36243282 DOI: 10.1016/j.anai.2022.10.004] [Reference Citation Analysis]
|
| 2 |
Racca F, Pellegatta G, Cataldo G, Vespa E, Carlani E, Pelaia C, Paoletti G, Messina MR, Nappi E, Canonica GW, Repici A, Heffler E. Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets. Front Physiol 2022;12:815842. [DOI: 10.3389/fphys.2021.815842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Keshvari MK, van Someren F, Sheikh S, Galea I. Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns. J Neuroimmunol 2021;361:577729. [PMID: 34624660 DOI: 10.1016/j.jneuroim.2021.577729] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 4 |
Diem L, Hoepner R, Bagnoud M, Salmen A, Chan A, Friedli C. Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature. J Neuroimmunol 2021;353:577505. [PMID: 33548621 DOI: 10.1016/j.jneuroim.2021.577505] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
